二肽基肽酶-4抑制剂西格列汀的抗炎及抗氧化应激机制研究

doi:10.12114/j.issn.1007-9572.2024.0268

摘要/Abstract

摘要： 2型糖尿病患病率呈现逐年上升的趋势，目前已知氧化应激和炎症反应可参与糖尿病的发生、发展。二肽基肽酶-4（DPP-4）抑制剂可以通过抑制DPP-4而增强肠促胰岛素效应，从而起到降糖作用，现已广泛应用于糖尿病患者的治疗中。目前已有研究显示DPP-4在多种炎症性疾病中表达上调，提示其可能参与炎症的发生。然而，关于DPP-4抑制剂在炎症及氧化应激中的作用机制的相关报道较少，因此本文通过综述DPP-4抑制剂西格列汀的抗炎及抗氧化应激机制，提出西格列汀在其他疾病的治疗中具有一定的应用前景，为后续相关研究开展提供借鉴。

关键词: 二肽基肽酶-4, 西格列汀, 消炎药，非甾类, 氧化应激, 糖尿病，2型, 综述

Abstract:

The prevalence rate of type 2 diabetes is increasing year by year. It is known that oxidative stress and inflammation can participate in the occurrence and development of diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors can enhance the incretin effect by inhibiting DPP-4, thus playing a hypoglycemic role, and have been widely used in the treatment of diabetes patients. Currently, studies have shown that DPP-4 expression is up-regulated in a variety of inflammatory diseases, suggesting that it may be involved in the occurrence of inflammation. However, there are few relevant reports on the mechanism of action of DPP-4 inhibitor in inflammation and oxidative stress. Therefore, this paper reviews the anti-inflammatory and antioxidant stress mechanism of sitagliptin, a DPP-4 inhibitor, and proposes that sitagliptin has certain application prospects in the treatment of other diseases, providing references for subsequent relevant studies.

Key words: Dipeptidyl peptidase-4 inhibitor, Sitagliptin, Anti-inflammatory agents, non-steroidal, Oxidative stress, Diabetes mellitus, type 2, Review

中图分类号:

R 971.1

竺晶,谢骥,胡晓霞. 二肽基肽酶-4抑制剂西格列汀的抗炎及抗氧化应激机制研究[J]. 中国全科医学, 2025, 28(12): 1543-1548. DOI: 10.12114/j.issn.1007-9572.2024.0268.
ZHU Jing,XIE Ji,HU Xiaoxia. Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor[J]. Chinese General Practice, 2025, 28(12): 1543-1548. DOI: 10.12114/j.issn.1007-9572.2024.0268.

参考文献 52

[1]	KHAN M A B，HASHIM M J，KING J K，et al. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends[J]. J Epidemiol Glob Health，2020，10（1）：107-111. DOI：10.2991/jegh.k.191028.001.
[2]	SALAZAR-GARCÍA M，CORONA J C. The use of natural compounds as a strategy to counteract oxidative stress in animal models of diabetes mellitus[J]. Int J Mol Sci，2021，22（13）：7009. DOI：10.3390/ijms22137009.
[3]	YARIBEYGI H，SATHYAPALAN T，ATKIN S L，et al. Molecular mechanisms linking oxidative stress and diabetes mellitus[J]. Oxid Med Cell Longev，2020，2020：8609213. DOI：10.1155/2020/8609213.
[4]	HALIM M，HALIM A. The effects of inflammation，aging and oxidative stress on the pathogenesis of diabetes mellitus（type 2 diabetes）[J]. Diabetes Metab Syndr，2019，13（2）：1165-1172. DOI：10.1016/j.dsx.2019.01.040.
[5]	ANURADHA R，SARASWATI M，KUMAR K G，et al. Apoptosis of beta cells in diabetes mellitus[J]. DNA Cell Biol，2014，33（11）：743-748. DOI：10.1089/dna.2014.2352.
[6]	XU Y，TANG G Y，ZHANG C，et al. Gallic acid and diabetes mellitus：its association with oxidative stress[J]. Molecules，2021，26（23）：7115. DOI：10.3390/molecules26237115.
[7]	WRONKA M，KRZEMIŃSKA J，MŁYNARSKA E，et al. The influence of lifestyle and treatment on oxidative stress and inflammation in diabetes[J]. Int J Mol Sci，2022，23（24）：15743. DOI：10.3390/ijms232415743.
[8]	JAYABAL D，JAYANTHI S，THIRUMALAISAMY R，et al. Molecular insights of anti-diabetic compounds and its hyaluronic acid conjugates against aldose reductase enzyme through molecular modeling and simulations study-a novel treatment option for inflammatory diabetes[J]. J Mol Model，2023，29（8）：238. DOI：10.1007/s00894-023-05616-2.
[9]	中华医学会内分泌学分会神经与内分泌学组. 基层医疗机构二肽基肽酶4抑制剂临床应用常见问题专家指导建议[J]. 中国糖尿病杂志，2022，30（2）：81-85. DOI：10.3969/j.issn.1006-6187.2022.02.001.
[10]	ÚJHELYI J，ÚJHELYI Z，SZALAI A，et al. Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice[J]. Regul Pept，2014，194/195：23-29. DOI：10.1016/j.regpep.2014.09.006.
[11]	ALOMAIR B M，AL-KURAISHY H M，AL-BUHADILY A K，et al. Is sitagliptin effective for SARS-CoV-2 infection：false or true prophecy?[J]. Inflammopharmacology，2022，30（6）：2411-2415. DOI：10.1007/s10787-022-01078-9.
[12]	WAUMANS Y，BAERTS L，KEHOE K，et al. The dipeptidyl peptidase family，prolyl oligopeptidase，and prolyl carboxypeptidase in the immune system and inflammatory disease，including atherosclerosis[J]. Front Immunol，2015，6：387. DOI：10.3389/fimmu.2015.00387.
[13]	DE ALMEIDA SALLES T，ZOGBI C，DE LIMA T M，et al. The contributions of dipeptidyl peptidaseⅣ to inflammation in heart failure[J]. Am J Physiol Heart Circ Physiol，2016，310（11）：H1760-1772. DOI：10.1152/ajpheart.00735.2015.
[14]	RAO X Q，ZHAO S，BRAUNSTEIN Z，et al. Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways[J]. EBioMedicine，2019，41：50-61. DOI：10.1016/j.ebiom.2019.01.065.
[15]	DRUCKER D，EASLEY C，KIRKPATRICK P. Sitagliptin[J]. Nat Rev Drug Discov，2007，6（2）：109-110. DOI：10.1038/nrd2245.
[16]	LI H，MENG Y，HE S W，et al. Macrophages，chronic inflammation，and insulin resistance[J]. Cells，2022，11（19）：3001. DOI：10.3390/cells11193001.
[17]	CHEN Y N，HU M R，WANG L，et al. Macrophage M1/M2 polarization[J]. Eur J Pharmacol，2020，877：173090. DOI：10.1016/j.ejphar.2020.173090.
[18]	DRARENI K，GAUTIER J F，VENTECLEF N，et al. Transcriptional control of macrophage polarisation in type 2 diabetes[J]. Semin Immunopathol，2019，41（4）：515-529. DOI：10.1007/s00281-019-00748-1.
[19]	TANG W L，DU M Q，ZHANG S，et al. Sitagliptin attenuates porphyromonas gingivalis virulence and inflammatory response in macrophage on titanium[J]. Arch Oral Biol，2023，149：105659. DOI：10.1016/j.archoralbio.2023.105659.
[20]	MIKHAEL E M，ONG S C，SHEIKH GHADZI S M. Efficacy and safety of sitagliptin in the treatment of COVID-19[J]. J Pharm Pract，2023，36（4）：980-987. DOI：10.1177/08971900221102119.
[21]	AL-KURAISHY H M，AL-GAREEB A I，QUSTY N，et al. Impact of sitagliptin on non-diabetic COVID-19 patients[J]. Curr Mol Pharmacol，2022，15（4）：683-692. DOI：10.2174/1874467214666210902115650.
[22]	KELLEY N，JELTEMA D，DUAN Y H，et al. The NLRP3 inflammasome：an overview of mechanisms of activation and regulation[J]. Int J Mol Sci，2019，20（13）：3328. DOI：10.3390/ijms20133328.
[23]	甯春，杨荣礼，杨雪，等. 达格列净联合西格列汀对老年糖尿病肾脏疾病患者肾功能及外周血清核苷酸结合寡聚化结构域样受体蛋白3炎性小体影响的研究[J]. 中国糖尿病杂志，2023，31（6）：418-423. DOI：10.3969/j.issn.1006-6187.2023.06.004.
[24]	ZHANG Y S，LIANG X J，BAO X F，et al. Toll-like receptor 4（TLR4）inhibitors：current research and prospective[J]. Eur J Med Chem，2022，235：114291. DOI：10.1016/j.ejmech.2022.114291.
[25]	ROFAEIL R R，AHMED S M，BAHAA H A，et al. Dipeptidyl peptidase-4 inhibitor：sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats[J]. Iran J Basic Med Sci，2022，25（11）：1396-1401. DOI：10.22038/IJBMS.2022.64552.14202.
[26]	ALLAM M M，IBRAHIM R M，EL GAZZAR W B，et al. Dipeptedyl peptidase-4（DPP-4）inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease[J]. Arch Physiol Biochem，2024，130（1）：87-95. DOI：10.1080/13813455.2021.1975758.
[27]	REN Y F，YE Y J，XUAN F L，et al. The effect of sitagliptin combined with rosiglitazone on autophagy and inflammation in polycystic ovary syndrome by regulating PI3K/AKT/mTOR and TLR4/NF-κB pathway[J]. Reprod Biol，2023，23（2）：100763. DOI：10.1016/j.repbio.2023.100763.
[28]	HEMATYAR J，RASHIDI H，ZAKERKISH M，et al. Effect of sitagliptin Versus glibenclamide on glycemic markers，lipid profile inflammatory and oxidative stress factors in type 2 diabetes patients：a double-blinded randomized controlled trial[J]. Maedica，2022，17（4）：762-770. DOI：10.26574/maedica.2022.17.4.762.
[29]	SUN X Y，XU Y，ZHOU J H. DPP4 inhibitor sitagliptin reduces inflammatory responses and mast cell activation in allergic rhinitis[J]. Pharmacology，2023，108（2）：166-175. DOI：10.1159/000528634.
[30]	XU L，SHAO F M. Sitagliptin protects renal glomerular endothelial cells against high glucose-induced dysfunction and injury[J]. Bioengineered，2022，13（1）：655-666. DOI：10.1080/21655979.2021.2012550.
[31]	KIM G D，NG H P，CHAN E R，et al. Kruppel-like factor 6 promotes macrophage inflammatory and hypoxia response[J]. FASEB J，2020，34（2）：3209-3223. DOI：10.1096/fj.201902221R.
[32]	ABD EL-FATTAH E E，SABER S，YOUSSEF M E，et al. AKT-AMPKα-mTOR-dependent HIF-1α activation is a new therapeutic target for cancer treatment：a novel approach to repositioning the antidiabetic drug sitagliptin for the management of hepatocellular carcinoma[J]. Front Pharmacol，2022，12：720173. DOI：10.3389/fphar.2021.720173.
[33]	BARNABEI L，LAPLANTINE E，MBONGO W，et al. NF-κB：At the borders of autoimmunity and inflammation[J]. Front Immunol，2021，12：716469. DOI：10.3389/fimmu.2021.716469.
[34]	MOZAFARI N，AZADI S，MEHDI-ALAMDARLOU S，et al. Inflammation：a bridge between diabetes and COVID-19，and possible management with sitagliptin[J]. Med Hypotheses，2020，143：110111. DOI：10.1016/j.mehy.2020.110111.
[35]	WANG X，KE J，ZHU Y J，et al. Dipeptidyl peptidase-4（DPP4）inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NF-κB pathway[J]. Cell Death Discov，2021，7（1）：236. DOI：10.1038/s41420-021-00625-7.
[36]	LIU X，KANG W Y，SHANG L L，et al. Sitagliptin inhibits lipopolysaccharide-induced inflammatory response in human gingival fibroblasts by blocking nuclear factor-κB signaling pathway[J]. West China J Stomatol，2021，39（2）：153-163. DOI：10.7518/hxkq.2021.02.005.
[37]	ZHENG Z C，LIANG P Y，HOU B H，et al. The effect of dipeptidyl peptidase IV on disease-associated microglia phenotypic transformation in epilepsy[J]. J Neuroinflammation，2021，18（1）：112. DOI：10.1186/s12974-021-02133-y.
[38]	ZHANG Q，XIAO X H，ZHENG J，et al. Maternal sitagliptin treatment attenuates offspring glucose metabolism and intestinal proinflammatory cytokines IL-6 and TNF-α expression in male rats[J]. PeerJ，2020，8：e10310. DOI：10.7717/peerj.10310.
[39]	HE X R，LI W G，XIE Y L，et al. Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice[J]. Int Immunopharmacol，2020，88：106945. DOI：10.1016/j.intimp.2020.106945.
[40]	TERAGAWA H，MORIMOTO T，FUJII Y，et al. Effect of anagliptin versus sitagliptin on inflammatory markers：sub-analysis from the REASON trial[J]. Diabetes Metab Syndr Obes，2020，13：4993-5001. DOI：10.2147/DMSO.S282968.
[41]	GALLUZZI L，KEPP O，TROJEL-HANSEN C，et al. Mitochondrial control of cellular life，stress，and death[J]. Circ Res，2012，111（9）：1198-1207. DOI：10.1161/CIRCRESAHA.112.268946.
[42]	JAESCHKE H. Reactive oxygen and mechanisms of inflammatory liver injury：present concepts[J]. J Gastroenterol Hepatol，2011，26（Suppl 1）：173-179. DOI：10.1111/j.1440-1746.2010.06592.x.
[43]	ZHAO X Q，HUANG P，YUAN J. Influence of glimepiride plus sitagliptin on treatment outcome，blood glucose，and oxidative stress in diabetic patients[J]. Am J Transl Res，2022，14（10）：7459-7466.
[44]	RAMOS H，BOGDANOV P，HUERTA J，et al. Antioxidant effects of DPP-4 inhibitors in early stages of experimental diabetic retinopathy[J]. Antioxidants，2022，11（7）：1418. DOI：10.3390/antiox11071418.
[45]	BANDOOKWALA M，SENGUPTA P. 3-Nitrotyrosine：a versatile oxidative stress biomarker for major neurodegenerative diseases[J]. Int J Neurosci，2020，130（10）：1047-1062. DOI：10.1080/00207454.2020.1713776.
[46]	TROCHA M，FLESZAR M G，FORTUNA P，et al. Sitagliptin modulates oxidative，nitrative and halogenative stress and inflammatory response in rat model of hepatic ischemia-reperfusion[J]. Antioxidants，2021，10（8）：1168. DOI：10.3390/antiox10081168.
[47]	HE F，RU X L，WEN T. NRF2，a transcription factor for stress response and beyond[J]. Int J Mol Sci，2020，21（13）：4777. DOI：10.3390/ijms21134777.
[48]	ELTAHIR H M，ELBADAWY H M，ALMIKHLAFI M A，et al. Sitagliptin ameliorates L-arginine-induced acute pancreatitis via modulating inflammatory cytokines expression and combating oxidative stress[J]. Front Pharmacol，2024，15：1389670. DOI：10.3389/fphar.2024.1389670.
[49]	ZHOU X，WANG W M，WANG C，et al. DPP4 inhibitor attenuates severe acute pancreatitis-associated intestinal inflammation via Nrf2 signaling[J]. Oxid Med Cell Longev，2019，2019：6181754. DOI：10.1155/2019/6181754.
[50]	KONG L M，DENG J，ZHOU X，et al. Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury[J]. Cell Death Dis，2021，12（10）：928. DOI：10.1038/s41419-021-04227-0.
[51]	CIVANTOS E，BOSCH E，RAMIREZ E，et al. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway[J]. Diabetes Metab Syndr Obes，2017，10：207-222. DOI：10.2147/DMSO.S132537.
[52]	ALI E A，TAYEL S G，ABBAS M A. Sitagliptin ameliorates busulfan-induced pulmonary and testicular injury in rats through antioxidant，anti-inflammatory，antifibrotic，and antiapoptotic effects[J]. Sci Rep，2023，13（1）：9794. DOI：10.1038/s41598-023-36829-3.